This edition of Gibson Dunn’s Federal Circuit Update for March 2024 summarizes the current status of several petitions pending before the Supreme Court, and recent Federal Circuit decisions concerning indefiniteness, obviousness, eligibility under Section 101, and the safe harbor provision under Section 271.
Client Alert | April 5, 2024
MergerLinks named New York partner Saee Muzumdar and San Francisco partner Ryan Murr among the top ten lawyers in its 2023 Top Mid Cap M&A Lawyers in North America list.
Firm News | March 18, 2024
Join our team of seasoned biopharma attorneys and industry leaders where we provide a recap of 2023 highlights for capital markets, M&A activity, royalty finance transactions and clinical funding arrangements, along with expectations for the Life Sciences deal market in 2024.
Webcasts | March 12, 2024
San Francisco partner Ryan Murr, Washington, D.C. partner Stephen Glover and San Francisco partner Branden Berns are the authors of "Behind The 'CVR Spin' Method Of Unlocking Assets In M&A" published by Law360 on March 11, 2024.
Article | March 11, 2024
Our Life Sciences update provides a recap of 2023 highlights for capital markets, M&A activity, royalty finance transactions, and clinical funding arrangements, along with expectations for 2024.
Client Alert | March 8, 2024
Our Federal Circuit Update summarizes the current status of several petitions pending before the U.S. Supreme Court, as well as recent Federal Circuit decisions concerning printed publications, written description, claim construction, and inequitable conduct.
Client Alert | March 5, 2024
This edition of Gibson Dunn’s Federal Circuit Update for January 2024 summarizes the current status of several petitions pending before the Supreme Court, and recent Federal Circuit decisions interpreting a forum selection clause in a settlement agreement, deciding the appropriate scope of an opposition to a motion to amend in an inter partes review proceeding, and reviewing the International Trade Commission’s determination of what satisfies the economic prong of the domestic industry requirement.
Client Alert | February 7, 2024
San Francisco of counsel Todd Trattner and partner Ryan Murr are the authors of "How Biotech Cos. Can Utilize Synthetic Royalty Financing" published by Law360 on February 1, 2024.
Article | February 1, 2024
This edition of Gibson Dunn’s Federal Circuit Update for December 2023 summarizes the current status of a couple petitions pending before the Supreme Court, and recent Federal Circuit decisions vacating a $1.5 billion damages award, interpreting infringement of method of use patents under the Hatch-Waxman Act, and reviewing claim constructions in an inter partes review.
| January 10, 2024
This edition of Gibson Dunn’s Federal Circuit Update summarizes the current status of several petitions pending before the Supreme Court, and recent Federal Circuit decisions concerning attorneys’ fees under 35 U.S.C. § 285, Article III standing, and the Board’s authority to issue a final written decision past the statutory deadline.
Client Alert | December 11, 2023
This edition of Gibson Dunn’s Federal Circuit Update summarizes the current status of several petitions pending before the Supreme Court, and recent Federal Circuit decisions concerning means-plus-function claims, apportionment, and forfeiting arguments not raised in an inter partes review (“IPR”) petition.
Client Alert | November 6, 2023
Our lawyers discuss recent Federal Food, Drug, and Cosmetic Act amendments requiring cybersecurity information in premarket submissions for cyber devices, as well as the potential implications for False Claims Act liability, and the rise of FCA cases for claims relating to cybersecurity in the healthcare industry more generally.
Client Alert | October 16, 2023
The U.S. Food and Drug Administration announced plans to formally classify laboratory-developed tests as medical devices under its regulations, subjecting these tests to extensive premarket review and postmarket compliance requirements.
Client Alert | October 9, 2023
This edition of Gibson Dunn’s Federal Circuit Update summarizes the current status of several petitions pending before the Supreme Court, additional materials released from the ongoing investigation by the Judicial Council of the Federal Circuit, and recent Federal Circuit decisions concerning motions to amend before the Patent Trial and Appeal Board, obviousness, and enablement.
Client Alert | October 3, 2023
The U.S. Food and Drug Administration recently published a draft guidance document proposing to regulate end-user output of prescription drug use-related software as labeling.
Client Alert | September 29, 2023
The 2023 edition of LMG Life Sciences highlighted six Gibson Dunn practices – Antitrust, Corporate, General Patent Litigation, Hatch-Waxman Patent Litigation (Branded), Mergers and Acquisitions, and White-Collar/Government Investigations – in the area of Life Sciences.
Firm News | September 27, 2023
Our Federal Circuit Update summarizes the status of several petitions pending before the U.S. Supreme Court, additional materials released from the ongoing investigation by the Judicial Council of the Federal Circuit, and recent Federal Circuit decisions.
Client Alert | September 6, 2023
Our Federal Circuit Update summarizes the current status of several petitions pending before the U.S. Supreme Court, the report and recommendation from the ongoing investigation by the Judicial Council of the Federal Circuit, and a number of recent Federal Circuit decisions.
Client Alert | August 7, 2023
Quidel’s merger with Ortho Clinical Diagnostics and GE HealthCare Technologies’ spinoff were named among the Impact Deals of the Year at the LMG Life Sciences Awards EMEA 2023.
Firm News | July 20, 2023
Gibson, Dunn & Crutcher LLP is advising Apogee Therapeutics, Inc. (Nasdaq: APGE), a biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications, on its upsized initial public offering.
Firm News | July 18, 2023
Gibson Dunn’s Federal Circuit Update summarizes the current status of several petitions pending before the Supreme Court, provides an update on a proceeding by the Judicial Council of the Federal Circuit, and summarizes recent Federal Circuit decisions concerning secondary considerations, inventorship, inherency, and enablement.
Client Alert | July 6, 2023
Gibson Dunn lawyers summarize the news and key cases from the Federal Circuit in April 2023.
Client Alert | May 1, 2023
Gibson Dunn lawyers summarize the latest news and key cases from the Federal Circuit.
Client Alert | April 3, 2023
The inaugural edition of Who’s Who Legal’s Thought Leaders: USA featured 39 partners from Gibson Dunn.
Firm News | January 9, 2023
Euromoney named 16 Gibson Dunn lawyers among its 2022 Rising Stars in the Americas, EMEA, and Asia-Pacific regions.
Firm News | October 12, 2022
The 2022 edition of LMG Life Sciences highlighted six Gibson Dunn practices – Antitrust, Corporate, General Patent Litigation, Mergers and Acquisitions, Hatch-Waxman Patent Litigation (Branded), and White-Collar/Government Investigations – in the area of Life Sciences.
Firm News | September 21, 2022
Best Lawyers® named 11 Gibson Dunn partners as the 2023 Lawyer of the Year in their respective practice areas and cities.
Firm News | August 18, 2022
Seven Gibson Dunn partners were recognized in the Who’s Who Legal 2022 Thought Leaders - Commercial Litigation and Who’s Who Legal 2022 Life Sciences guides.
Firm News | April 1, 2022
Law360 named Gibson Dunn a Firm of the Year for 2021 in its January 17, 2022 article "The Firms That Dominated in 2021,” featuring nine firms that received the most Practice Group of the Year awards.
Firm News | January 19, 2022
The 2021/22 edition of LMG Life Sciences highlighted five Gibson Dunn practices – Antitrust, Competition & Antitrust, Corporate, General Patent Litigation, Mergers and Acquisitions, White-Collar/Government Investigations – in the area of Life Sciences.
Firm News | September 29, 2021
LMG Life Sciences named Gibson Dunn as the “General Patent Litigation Firm of the Year” at its annual awards ceremony. In addition, three Gibson Dunn partners were named Litigator of the Year in their respective practices.
Firm News | September 23, 2021
Law360 named six Gibson Dunn partners among its 2021 MVPs. The Law360 MVP Awards feature lawyers who have “distinguished themselves from their peers by securing hard-earned successes in high-stakes litigation, complex global matters and record-breaking deals.” The list was published on August 30, 2021.
Firm News | September 8, 2021
For the past several years, life sciences companies have been a frequent target of securities class action lawsuits. In this webcast, a panel from Gibson Dunn and Cornerstone Research provide an overview of trends and developments in such lawsuits, and discuss how the U.S. Supreme Court's Omnicare decision may be applied in life sciences cases.
Webcasts | June 16, 2021
Law360 named Gibson Dunn a Firm of the Year for 2020 in its November 30, 2020 article "The Firms That Dominated in 2020,” featuring eight firms that received the most Practice Group of the Year awards.
Firm News | December 2, 2020
In the 2020 edition of LMG Life Sciences, Gibson Dunn was recognized in six practice areas: Competition & Antitrust, General Corporate, General Patent Litigation, Mergers & Acquisitions, Product Liability & Recall and White-Collar/Government Investigation.
Firm News | October 8, 2020
Expert Guides has named 13 Gibson Dunn partners to its 2020 Guide to the World’s Leading Women in Business Law, which recognizes top female legal practitioners advising on business law.
Firm News | September 22, 2020
Gibson, Dunn & Crutcher LLP is pleased to announce that Robert Phillips has joined the firm’s San Francisco office as a partner. Phillips, formerly a partner at Cooley LLP, will continue to focus on corporate and capital markets transactions for life sciences and technology companies.
Press Releases | September 8, 2020
New York partner Jane Love was named to Managing IP’s Top 250 Women in IP 2020, which recognizes the “senior female IP practitioners in private practice who have performed exceptionally for their clients and firms in the past year.” The list was published May 29, 2020.
Firm News | June 8, 2020
Gibson Dunn reports on the steady pace of patent litigation and patent review filings during the COVID-19 pandemic, and notes that some aspects of ongoing patent litigation are also proceeding as usual.
Client Alert | May 13, 2020
In this webcast, a panel of Gibson Dunn lawyers discuss how to navigate new and evolving approaches to antitrust enforcement and litigation within innovative health care markets.
Webcasts | May 6, 2020
The National Law Journal named New York partner Jane Love among its 2020 Health Care/Life Science Trailblazers.
Firm News | April 1, 2020
The COVID-19 outbreak has caused major disruptions in global economies, including to life sciences companies conducting clinical trials and manufacturing and marketing pharmaceutical products. Gibson Dunn lawyers note ten actions that life sciences companies may wish to consider in light of the pandemic.
Client Alert | March 30, 2020
Gibson, Dunn & Crutcher LLP is pleased to announce that Karen Spindler has joined the firm’s San Francisco office. Spindler, formerly a partner at Goodwin Procter, will continue to focus on advising life sciences companies on complex corporate, commercial and intellectual property transactions.
Press Releases | March 17, 2020
Law360 named nine Gibson Dunn partners among its 2019 MVPs and noted that Gibson Dunn was one of two law firms with the most MVPs this year. Law360 MVPs feature lawyers who have “distinguished themselves from their peers by securing hard-earned successes in high-stakes litigation, complex global matters and record-breaking deals.” The list was published on November 12, 2019.
Firm News | November 12, 2019
The Best Lawyers in America® 2020 has recognized 158 Gibson Dunn attorneys in 54 practice areas. Additionally, 48 lawyers were recognized in Best Lawyers International in Belgium, Brazil, France, Germany, Singapore, United Arab Emirates and United Kingdom.
Firm News | August 15, 2019
Four Gibson Dunn partners were recognized by Who’s Who Legal in their respective fields. In Who’s Who Legal Thought Leaders – Tax 2019, two partners were recognized: London partner Sandy Bhogal and New York partner Eric Sloan.
Firm News | June 18, 2019
On May 20, 2019, the Supreme Court unanimously held that courts, not juries, must decide as a matter of law whether there is “clear evidence” that the FDA would not have approved a proposed label warning about a risk of a drug, thereby preempting a state-law failure-to-warn claim based on that same risk.
Client Alert | May 20, 2019
Gibson Dunn lawyers discuss enforcement and regulatory developments in the drug and device space during 2018, as well as notable developments in drug pricing and for device manufacturers.
Client Alert | February 12, 2019
The 2018 edition of LMG Life Sciences highlighted six Gibson Dunn practices – Corporate, Mergers & Acquisitions, Intellectual property, Antitrust, Product Liability and White-Collar/Government Investigation – in the area of Life Sciences.
Firm News | October 31, 2018
On October 16, 2018, the Securities and Exchange Commission issued a report warning public companies about the importance of internal controls to prevent cyber fraud. The report described the SEC Division of Enforcement's investigation of multiple public companies which had collectively lost nearly $100 million in a range of cyber-scams typically involving phony emails requesting payments to vendors or corporate executives.
Client Alert | October 17, 2018